Will methylation assays be part of a full molecular strategy to improve clinical management of cervical neoplasia?
- PMID: 39320908
- PMCID: PMC11485881
- DOI: 10.1080/17501911.2024.2402684
Will methylation assays be part of a full molecular strategy to improve clinical management of cervical neoplasia?
Keywords: DNA methylation; cervical cancer management; cervical cancer screening; cervical intraepithelial neoplasia; human papillomavirus.
Conflict of interest statement
M El-Zein and EL Franco hold a patent related to the discovery “DNA methylation markers for early detection of cervical cancer”, registered at the Office of Innovation and Partnerships, McGill University, Montreal, QC, Canada (October 2018).
EL Franco served as an occasional advisor for companies involved with HPV vaccines (Merck, GlaxoSmithKline) and HPV diagnostics (Roche Diagnostics) and as a Steering Committee Member for a publicly funded study in Finland that received support from GlaxoSmithKline.
References
-
- Canadian Partnership Against Cancer . HPV immunization for the prevention of cervical cancer. 2021. https://www.partnershipagainstcancer.ca/topics/hpv-immunization-policies/ (accessed 2024-04-20).
-
- Kaiser Family Foundation . The HPV Vaccine: access and Use in the U.S. 2024. Available from: https://www.kff.org/womens-health-policy/fact-sheet/the-hpv-vaccine-acce... (accessed 2024-04-20).